WEKO3
アイテム
肝細胞癌におけるCD68、CD163ならびに葉酸レセプターβ陽性マクロファージの予後的意義
http://hdl.handle.net/10232/00031371
http://hdl.handle.net/10232/000313718aae2d6c-830e-4a3f-aa79-75b27ada34c8
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Diss_南_幸次_ISK571_2020 (1.7 MB)
|
|
|
|
Abstract_南_幸次_4509810254_2020 (66.4 kB)
|
|
|
|
Result_Minami_Koji_isk_571 (815.6 kB)
|
|
|
|
Comments_Minami_Koji_isk_571 (384.1 kB)
|
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2020-10-05 | |||||
| タイトル | ||||||
| タイトル | Prognostic Significance of CD68, CD163 and Folate receptor beta Positive Macrophage in Hepatocellular Carcinoma | |||||
| タイトル言語 | en | |||||
| タイトル | ||||||
| タイトル | 肝細胞癌におけるCD68、CD163ならびに葉酸レセプターβ陽性マクロファージの予後的意義 | |||||
| タイトル言語 | ja | |||||
| 著者 |
南, 幸次
× 南, 幸次 |
|||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | hepatocellular carcinoma | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | cluster of differentiation 68 | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | cluster of differentiation 163 | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | folate receptor β | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | macrophage | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||
| 資源タイプ | doctoral thesis | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Cluster of differentiation (CD)68 may be used as a pan‑macrophage or M1 marker, whereas CD163 may be used as an M2 marker. Furthermore, folate receptor (FR)β exhibits an M2‑like functional profile. In the present study, CD68 and CD163 were used to evaluate and classify tumor‑associated macrophages (TAMs). The expression of CD68, CD163 and FRβ by TAMs in hepatocellular carcinoma (HCC) Tissues was investigated. Samples from 105 patients with HCC were evaluated using immunohistochemistry. The results revealed that CD68 and CD163 overexpression was associated with a worse prognosis. The number of CD68 positive cells observed was significantly higher in patients with stage IV cancer. Furthermore, an increase in CD68 positive cells was observed in patients with median tumor size ≥3.5 cm and in patients with poorly differentiated HCC. The number of CD163 positive cells was also significantly increased in patients with median tumor size ≥3.5 cm and in those with poorly differentiated HCC. A low CD163/68 ratio was correlated with a worse outcome. The ratio was significantly lower in patients with stage IV cancer, patients with des‑gamma‑carboxy prothrombin abnormalities, patients with blood vessel infiltration and patients with intrahepatic metastasis. The number of FRβ positive cells was not correlated with clinicopathological features. The results of the present study indicate that overexpression of CD68 and CD163 may be associated with a worse patient outcome. The evaluation of CD68 and CD163 positive cells in a cancer microenvironment is controversial. TAMs are not simply cells with single markers or restricted M1 or M2 phenotypes; they are more diverse and heterogeneous. Further studies are required to determine the cross‑interaction between diverse TAMs and the tumor microenvironment. Koji Minami, Kiyokazu Hiwatashi, Shinichi Ueno, Masahiko Sakoda, Satoshi Iino, Hiroshi Okumura, Motoyuki Hashiguchi, Yota Kawasaki, Hiroshi Kurahara, Yuko Mataki, Kosei Maemura, Hiroyuki Shinchi, Shoji Natsugoe Prognostic significance of CD68, CD163 and Folate receptor‑β positive macrophages in hepatocellular carcinoma Experimental and Therapeutic Medicine 15(5) 4465-4476 2018 https://doi.org/10.3892/etm.2018.5959 |
|||||
| 内容記述言語 | en | |||||
| 作成日 | ||||||
| 日付 | 2020-09-04 | |||||
| 日付タイプ | Collected | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| NDC | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 490 | |||||
| ファイル（説明） | ||||||
| 内容記述 | 博士論文全文, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨 | |||||
| 公開者・出版者 | ||||||
| 出版者 | Spandidos Publications | |||||
| 出版者言語 | en | |||||
| 公開者・出版者 | ||||||
| 出版者 | 鹿児島大学 | |||||
| 出版者言語 | ja | |||||
| 公開者・出版者 | ||||||
| 出版者 | カゴシマ ダイガク | |||||
| 出版者言語 | ja-Kana | |||||
| 備考 | ||||||
| 備考 | 【指導教員:夏越祥次/大塚隆生】 | |||||
| date.appl | ||||||
| appl | 【学位申請日】2020-04-01 | |||||
| 学位名 | ||||||
| 学位名の言語 | ja | |||||
| 学位名 | 博士(医学) | |||||
| 学位名 | ||||||
| 学位名の言語 | en | |||||
| 学位名 | Doctor of Philosophy in Medical Science | |||||
| 学位授与機関名 | ||||||
| 学位授与機関識別子Scheme | kakenhi | |||||
| 学位授与機関識別子 | 17701 | |||||
| 学位授与機関名の言語 | ja | |||||
| 学位授与機関名 | 鹿児島大学 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2020-09-16 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 甲総研第571号 | |||||
